These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 11865275

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Effect of long-term transfusion on growth in children with sickle cell anemia: results of the STOP trial.
    Wang WC, Morales KH, Scher CD, Styles L, Olivieri N, Adams R, Brambilla D, STOP Investigators.
    J Pediatr; 2005 Aug; 147(2):244-7. PubMed ID: 16126058
    [Abstract] [Full Text] [Related]

  • 3. Use of hydroxyurea in children with sickle cell disease: what comes next?
    Ohene-Frempong K, Smith-Whitley K.
    Semin Hematol; 1997 Jul; 34(3 Suppl 3):30-41. PubMed ID: 9317199
    [Abstract] [Full Text] [Related]

  • 4. Hydroxyurea in sickle cell disease patients from Eastern Saudi Arabia.
    Al-Jam'a AH, Al-Dabbous IA.
    Saudi Med J; 2002 Mar; 23(3):277-81. PubMed ID: 11938415
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effects of hydroxyurea on the membrane of erythrocytes and platelets in sickle cell anemia.
    Covas DT, de Lucena Angulo I, Vianna Bonini Palma P, Zago MA.
    Haematologica; 2004 Mar; 89(3):273-80. PubMed ID: 15020264
    [Abstract] [Full Text] [Related]

  • 7. Hydroxyurea for the treatment of sickle cell anemia.
    Platt OS.
    N Engl J Med; 2008 Mar 27; 358(13):1362-9. PubMed ID: 18367739
    [No Abstract] [Full Text] [Related]

  • 8. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy.
    Ware RE, Zimmerman SA, Sylvestre PB, Mortier NA, Davis JS, Treem WR, Schultz WH.
    J Pediatr; 2004 Sep 27; 145(3):346-52. PubMed ID: 15343189
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea.
    Lanzkron S, Haywood C, Segal JB, Dover GJ.
    Am J Hematol; 2006 Dec 27; 81(12):927-32. PubMed ID: 16924648
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Hydroxyurea and new agents for the treatment of sickle cell disease.
    Rodgers GP.
    Clin Adv Hematol Oncol; 2004 Nov 27; 2(11):713-5. PubMed ID: 16163257
    [No Abstract] [Full Text] [Related]

  • 15. Hydroxyurea and growth in young children with sickle cell disease.
    Rana S, Houston PE, Wang WC, Iyer RV, Goldsmith J, Casella JF, Reed CK, Rogers ZR, Waclawiw MA, Thompson B, BABY HUG Investigators.
    Pediatrics; 2014 Sep 27; 134(3):465-72. PubMed ID: 25157002
    [Abstract] [Full Text] [Related]

  • 16. Hydroxyurea therapy associated with declining serum levels of magnesium in children with sickle cell anemia.
    Altura RA, Wang WC, Wynn L, Altura BM, Altura BT.
    J Pediatr; 2002 May 27; 140(5):565-9. PubMed ID: 12032523
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.